Trial Profile
Pilot Study, Without Direct Individual Benefice, of Biological Effect of Tarceva (OSI-774) [Erlotinib] at Posology of 150 mg by Day for Patients Stricken by ENT Epidermoid Carcinoma Waiting for First Surgical Picking up
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Head and neck cancer
- Focus Pharmacodynamics
- 26 Jun 2008 New trial record.